Daiichi Sankyo Korea and Daewoong announce co-promotion agreement of ‘Lixiana’
Daiichi Sankyo Korea(CEO Dae-joong Kim) and Daewoong Pharmaceutical(CEO Jong-ok Lee) announced a co-promotion agreement of ‘Lixiana,’ an oral anticoagulant, on the 21st.
Daiichi Sankyo Korea and Daewoong Pharmaceutical are planning to cooperate on sales and marketing, and launch 3 different volu...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
